immunogenicity induced pluripotent stem cells 
induced pluripotent stem cells ipscs reprogrammed somatic cells defined factors hold great promise regenerative medicine renewable source autologous cells1- whereas generally assumed autologous cells immune-tolerated recipient ipscs derived immunogenicity vigorously examined show whereas embryonic stem cells escs derived inbred c57bl/ b6 mice can efficiently form teratomas b6 mice without evident immune rejection allogeneic escs /svj mice fail form teratomas b6 mice due rapid rejection recipients b6 mouse embryonic fibroblasts mefs reprogrammed ipscs either retroviral approach vipscs novel episomal approach eipscs causes genomic integration contrast b6 escs teratomas formed b6 vipscs mostly immune-rejected b6 recipients addition majority teratomas formed b6 eipscs immunogenic b6 mice t cell infiltration apparent tissue damage regression observed small fraction teratomas global gene expression analysis teratomas formed b6 escs eipscs revealed number genes frequently over-expressed teratomas derived eipscs several gene products shown contribute directly immunogenicity b6 eipsc-derived cells b6 mice findings indicate contrast derivatives escs abnormal gene expression cells differentiated ipscs can induce t-cell-dependent immune response syngeneic recipients therefore immunogenicity therapeutically valuable cells derived patient-specific ipscs evaluated clinical application autologous cells patients 
